|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/25/20 Akers Biosciences, Inc. 10-K 12/31/19 80:11M M2 Compliance/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 995K
2: EX-3.10 Articles of Incorporation/Organization or Bylaws HTML 28K
3: EX-4.12 Instrument Defining the Rights of Security Holders HTML 52K
4: EX-21.1 Subsidiaries List HTML 23K
5: EX-23.1 Consent of Experts or Counsel HTML 23K
6: EX-31.1 Certification -- §302 - SOA'02 HTML 30K
7: EX-31.2 Certification -- §302 - SOA'02 HTML 30K
8: EX-32.1 Certification -- §906 - SOA'02 HTML 25K
71: R1 Document and Entity Information HTML 59K
35: R2 Consolidated Balance Sheets HTML 107K
25: R3 Consolidated Balance Sheets (Parenthetical) HTML 45K
47: R4 Consolidated Statements of Operations and HTML 96K
Comprehensive Loss
70: R5 Consolidated Statement of Changes in Shareholders' HTML 87K
Equity
34: R6 Consolidated Statement of Changes in Shareholders' HTML 29K
Equity (Parenthetical)
23: R7 Consolidated Statements of Cash Flows HTML 132K
46: R8 Organization and Description of Business HTML 29K
72: R9 Significant Accounting Policies HTML 105K
27: R10 Recent Developments, Liquidity and Management's HTML 30K
Plans
37: R11 Inventories HTML 32K
79: R12 Property, Plant and Equipment HTML 32K
54: R13 Intangible Assets HTML 40K
28: R14 Trade and Other Payables HTML 29K
38: R15 Share-based Compensation HTML 78K
80: R16 Equity HTML 43K
55: R17 Income Taxes HTML 43K
29: R18 Commitments and Contingencies HTML 67K
36: R19 Related Parties HTML 30K
64: R20 Revenue Information HTML 34K
56: R21 Employee Benefit Plan HTML 26K
15: R22 Subsequent Events HTML 41K
41: R23 Significant Accounting Policies (Policies) HTML 176K
65: R24 Significant Accounting Policies (Tables) HTML 43K
57: R25 Inventories (Tables) HTML 30K
16: R26 Property, Plant and Equipment (Tables) HTML 32K
42: R27 Intangible Assets (Tables) HTML 41K
63: R28 Trade and Other Payables (Tables) HTML 28K
58: R29 Share-based Compensation (Tables) HTML 84K
53: R30 Income Taxes (Tables) HTML 44K
77: R31 Commitments and Contingencies (Tables) HTML 28K
40: R32 Revenue Information (Tables) HTML 35K
31: R33 Significant Accounting Policies (Details HTML 115K
Narrative)
52: R34 Significant Accounting Policies - Schedule of HTML 29K
Marketable Securities (Details)
76: R35 Significant Accounting Policies - Schedule of HTML 41K
Estimated Useful Life of Property Plant and
Equipment (Details)
39: R36 Significant Accounting Policies - Schedule of HTML 28K
Estimated Useful Life of Other Intangible Assets
(Details)
30: R37 Significant Accounting Policies - Schedule of HTML 35K
Anti-dilutive Securities Excluded from Computation
of Earnings Per Share (Details)
51: R38 Recent Developments, Liquidity and Management's HTML 33K
Plans (Details Narrative)
78: R39 Inventories (Details Narrative) HTML 33K
62: R40 Inventories - Schedule of Inventories (Details) HTML 37K
68: R41 Property, Plant and Equipment (Details Narrative) HTML 26K
44: R42 Property, Plant and Equipment - Schedule of HTML 49K
Property, Plant and Equipment (Details)
18: R43 Intangible Assets (Details Narrative) HTML 29K
61: R44 Intangible Assets - Schedule of Finite-Lived HTML 36K
Intangible Assets (Details)
67: R45 Intangible Assets - Schedule of Estimated HTML 40K
Aggregate Amortization Expense of Fiscal Years
(Details)
43: R46 Trade and Other Payables - Schedule of Trade and HTML 34K
Other Payables (Details)
17: R47 Share-based Compensation (Details Narrative) HTML 75K
60: R48 Share-based Compensation - Summary of Stock HTML 88K
Options Activity (Details)
69: R49 Share-based Compensation - Summary of Restricted HTML 52K
Stock Units Activity (Details)
74: R50 Share-based Compensation - Summary of Warrant HTML 85K
Activity (Details)
48: R51 Equity (Details Narrative) HTML 96K
21: R52 Income Taxes (Details Narrative) HTML 44K
32: R53 Income Taxes - Schedule of Income Tax (Benefit)/ HTML 37K
Provision (Details)
75: R54 Income Taxes - Schedule of Reconciliation of HTML 44K
Income Taxes using Statutory U.S. Income Tax Rate
and Benefit from Income Taxes (Details)
49: R55 Income Taxes - Schedule of Deferred Tax Assets and HTML 38K
Related Valuation Allowances (Details)
22: R56 Commitments and Contingencies (Details Narrative) HTML 111K
33: R57 Commitments and Contingencies - Schedule of Lease HTML 29K
Commitments (Details)
73: R58 Related Parties (Details Narrative) HTML 42K
50: R59 Revenue Information (Details Narrative) HTML 27K
19: R60 Revenue Information - Schedule of Revenue by HTML 31K
Product Lines (Details)
45: R61 Revenue Information - Schedule of Revenue by HTML 28K
Geographic Area Determined Based On Location of
Customers (Details)
66: R62 Employee Benefit Plan (Details Narrative) HTML 31K
59: R63 Subsequent Event (Details Narrative) HTML 62K
20: XML IDEA XML File -- Filing Summary XML 140K
26: EXCEL IDEA Workbook of Financial Reports XLSX 96K
9: EX-101.INS XBRL Instance -- aker-20191231 XML 1.40M
11: EX-101.CAL XBRL Calculations -- aker-20191231_cal XML 192K
12: EX-101.DEF XBRL Definitions -- aker-20191231_def XML 658K
13: EX-101.LAB XBRL Labels -- aker-20191231_lab XML 1.37M
14: EX-101.PRE XBRL Presentations -- aker-20191231_pre XML 884K
10: EX-101.SCH XBRL Schema -- aker-20191231 XSD 248K
24: ZIP XBRL Zipped Folder -- 0001493152-20-004650-xbrl Zip 161K
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-1 (File No. 333-234447 and 333-235359) of Akers Biosciences, Inc. of our report dated March 24, 2020 relating to the consolidated financial statements, which appears in this Form 10-K.
/s/ Morison Cogen LLP
Blue Bell, Pennsylvania
C:
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed as of: | 3/25/20 | |||
| Filed on: | 3/24/20 | 8-K, CORRESP | ||
| For Period end: | 12/31/19 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/19/21 MyMD Pharmaceuticals, Inc. S-4/A 121:17M M2 Compliance LLC/FA 3/01/21 MyMD Pharmaceuticals, Inc. 10-K 12/31/20 69:7.8M M2 Compliance LLC/FA 1/15/21 MyMD Pharmaceuticals, Inc. S-4 6:9.5M M2 Compliance LLC/FA 11/16/20 MyMD Pharmaceuticals, Inc. 10-Q 9/30/20 57:6.6M M2 Compliance LLC/FA 10/21/20 MyMD Pharmaceuticals, Inc. 10-K/A 12/31/19 6:1.1M M2 Compliance LLC/FA 9/08/20 MyMD Pharmaceuticals, Inc. 424B3 1:153K M2 Compliance LLC/FA 8/18/20 MyMD Pharmaceuticals, Inc. S-3 3:265K M2 Compliance LLC/FA 8/14/20 MyMD Pharmaceuticals, Inc. 10-Q 6/30/20 59:6M M2 Compliance LLC/FA |